Get E&O weekly. Subscribe
Digital health research from Brian Dolan.
Welcome to E&O.
Last week's newsletter had a 59 percent open rate. Here's what's happening this week:
I've been heads-down on The 4,400-word Hinge Health Report this past week, which is why this newsletter is mostly just a prompt to dig into the report. More background on it after a few links below...
- As I predicted in last week's newsletter, Akili Interactive, which has been waiting on FDA authorization for a long time, launched a version of its ADHD digital therapeutic, Endeavor, under FDA's latest non-enforcement guidance. No cost to families who qualify. The company is still pursuing 510(K) too: More here.
- Samsung just received authorization from South Korea's medical device regulatory agency to market its SaMD cuffless blood pressure monitoring app: "Once your Galaxy Watch Active2 device has been